From June 4th-6th, ASBM exhibited at the 2019 BIO International Convention held in Philadelphia, PA. Each year, the BIO International Convention attracts approximately 16,000 attendees from more than 5,000 companies and from 70 different countries.

ASBM was represented at the booth by Andrew Spiegel, ASBM Steering Committee member and executive director of the Global Colon Cancer Association. At ASBM’s booth, attendees met with Mr. Spiegel and discussed key biosimilar policy issues including biosimilar naming and non-medial switching policy. ASBM’s booth offered a variety of literature on these and other topics including the biosimilar approval process, indication extrapolation, product labeling, and the results of recent physician surveys regarding their biosimilar policy preferences.

While at the BIO Convention, Spiegel also participated in a panel discussion with other patient advocates and biologic manufacturers to discuss the importance to patients of building a sustainable biosimilar market. Read more about the 2019 Bio Convention here.